If the issue is reasonably priced, investors can apply for this IPO as the promoter Mr Satish Wagh has a very credible image, known for his strong drive and honesty. He needs no further introduction as the company under his able leadership has consistently performed over many years. The Balance Sheet is the biggest certificate.

Supriya Lifescience will launch its maiden public offer on December 16, 2021. The offer will close on December 20. The company is yet to announce the price band; however, it plans to mop up Rs 700 crore through its IPO. It will comprise a fresh issuance of shares worth Rs 200 crore and an offer for sale of Rs 500 crore by promoter Satish Waman Wagh, who holds 99.98 percent equity shareholding in Supriya Lifescience. The net proceeds from fresh issue will be utilised for capital expenditure requirements, repaying of debts, and general corporate purposes.


Supriya Lifescience has been constantly reporting robust financial numbers last many quarters. It has recorded 68.7 percent growth in profit for the financial year FY21, compared to Rs 73.4 crore profit in previous year. Revenue during the same period jumped 23.7 percent to Rs 385.36 crore from Rs 311.64 crore. The company reported profit of Rs 65.96 crore on revenue of Rs 224.8 crore in the six-month period ended September 2021.


This active pharmaceuticals ingredients manufacturer has niche product offerings of 38 active pharmaceuticals ingredients (APIs) focused on diverse therapeutic segments. It has consistently been the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India, contributing to 45-50 percent and 60-65 percent, respectively, of the API exports from India, between fiscal 2017 and 2021.

The Company

Supriya Lifescience Ltd., with a State-of-the-art US FDA and EU GMP certified facilities at four locations, has a global footprint that extends across 105 countries. The Company is pioneers in therapeutic segments like – Anti-Histamine, Anti-Allergic, Vitamins and Anti- Asthmatic. Continuously has been recording a CAGR of 22 per cent growth in a highly dynamic and constantly changing industry and market. It has been reinventing itself with various innovative products. Its diverse repertoire of Active Pharmaceutical Ingredients includes over 60 products that enjoy the implicit trust of a loyal global clientele. Its consistency in quality, strong regulatory support and on-time delivery has made the Company a preferred destination and reliable source material supplier. Registered in over 35 countries, the Company meets the most demanding quality standards.

& The Promoter

Promoted by a dynamic and visionary entrepreneur Mr Satish Wagh, CMD of Supriya Lifescience, the Company has turned out to be a world class enterprise. Unlike other Indian promoters, Mr Wagh is highly qualified with the perfect blend of technical knowledge and business acumen. He was elected Chairman of the Chemical Export Promotion Council (CHEMECXIL). With his vast and varied experience of over three and a half decades in the Pharmaceutical Industry, Satish Wagh is invited as Guest Lecturer at several reputed academic institutions, including the IIMs, where he inspires, motivates and shares his experience with young business school graduates.

Topics you may be interested in:
About the author: IE&M Team
IE&M Team
Indian Economy & Market is an Indian media and information platform producing data-backed news and analysis on all the vital elements at the intersection of the economy, stock markets, mutual fund, insurance, commodities, currency, technology, startups and business.

More articles by the author

Table of Contents